Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing access to effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Biotechnology

Healthcare

Bristol Myers Squibb

BMS first teamed up with Medidata back in 2016, turning to the company's cloud-based software to help run clinical trials in cancer and other indications.

BMS extends partnership with Medidata to adopt new digital trial management tools

– “Function-first” small molecule discovery company launched by Versant Ventures’ Inception Discovery Engine

Light Horse Therapeutics Debuts With $62 Million Series A Financing

Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The r

Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company

Why is Bristol-Myers Squibb Company (BMY) among the Best High-Yield Dividend Stocks to Invest In?

Why Is Bristol-Myers Squibb Company (BMY) Among the Best High-Yield Dividend Stocks to Invest In?

New Initiative in Partnership with Africa Centers for Disease Control (Africa CDC) and Local Ministries of Health Builds on Decades of Capacity Building to combat HIV and Pediatric CancerHOUSTON, Jan. 17, 2025 /PRNewswire/ -- Texas Children's Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in their joint efforts to dramatically improve children's health in Sub-Saharan Africa with the launch of a groundbreaking program to address one of the most urgent threats facing the region: sickle cell disease (SCD)

Bristol Myers Squibb Foundation, Texas Children'S Global Hope,  Baylor College Of Medicine Global Health Launch Program To Combat Sickle Cell Disease In Sub-Saharan Africa

Under the agreement, ArsenalBio will be responsible for discovering and building preclinical candidates against multiple targets, and Bristol Myers Squibb will have the option to obtain an exclusive worldwide license to develop and commercialize preclinical candidates.

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

Bristol Myers Squibb (NYSE: BMY) has announced its upcoming participation at J.P. Morgan's 43rd Annual Healthcare Conference.

Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference

BioArctic enters global license agreement with Bristol Myers Squibb.

BioArctic enters global license agreement with Bristol Myers Squibb

Exome Asset Management LLC invests $4.04 million in Bristol-Myers Squibb (NYSE:BMY).

Exome Asset Management LLC Invests $4.04 Million in Bristol-Myers Squibb (NYSE:BMY)

Recent News: Bristol-Myers Squibb filed a lawsuit last week against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

Collaboration underscores Bristol Myers Squibb’s commitment to unleashing the power of digital technologies to advance its mission to discover, develop, and deliver Innovative medicines that help patients prevail over serious diseasesNew York – Jan. 7, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers Squibb to help enhance the company’s clinical research processes, advance patient outcomes, and foster personalized healthcare.Bristol Myers Squibb will continue to leverage the Medidata Platform, and is working with Medidata to evaluate additional components of their suite of products including AI and advanced analytics, innovative data management solutions, and the newly launched Medidata Clinical Data Studio to help manage, monitor, and analyze its clinical trials. This strategic extension will enable Bristol Myers Squibb to deepen engagement with trial sites and patients while streamlining processes and expediting the delivery of life-changing therapies to those in need.“We are honored to continue working with BMS in their efforts to leverage the Medidata Platform and unify more of their clinical trial ecosystem.” said Janet Butler, executive vice president, head of global sales, Medidata. “As the use of AI evolves quickly in our industry, it’s exciting to see leaders like BMS adopt practical and impactful technology beyond EDC to speed research and add efficiency for sites.”About MedidataMedidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster

Medidata Signs Multi-Year Agreement With Bristol Myers Squibb To Extend Relationship And Continue Company’S Use Of Platform

Develops and delivers biopharmaceutical medicines

Bristol Myers Squibb

Develops and delivers biopharmaceutical medicines

Bristol Myers Squibb

Develops and delivers biopharmaceutical medicines

About

Simplify's Take

What believers are saying

What critics are saying

What makes Bristol Myers Squibb unique

Benefits

Recently Posted Jobs

Bristol Myers Squibb is Hiring for 0 Jobs on Simplify!